07.18.13
Alkermes will present an overview of its pipeline at an R&D Day meeting for analysts and investors, highlighting three new drug candidates: a monomethyl fumarate (MMF) prodrug for the treatment of multiple sclerosis; ALKS 7106 for the treatment of pain; and RDB 1419, a cancer immunotherapy candidate based on interleukin-2 (IL-2) and its receptors, the company’s first proprietary biologic .
In addition, the company will provide details on later-stage pipeline candidates including: commercial plans for aripiprazole lauroxil, a once-monthly, long-acting atypical antipsychotic currently in Phase III development for the treatment of schizophrenia; review of the Phase II data for ALKS 5461, an opioid modulator with a novel mechanism for the treatment of major depressive disorder (MDD); and the clinical rationale and development plan, including initiation of a Phase II study for ALKS 3831, an oral compound designed as a broad spectrum antipsychotic treatment for schizophrenia.
“The three new drug candidates that we are unveiling exemplify the productivity of R&D at Alkermes — which now spans small molecules and biologics — and represent significant opportunities for us to address unmet needs for patients with major, chronic diseases: multiple sclerosis, pain and cancer,” said Elliot Ehrich, M.D., chief medical officer of Alkermes. “Our distinctive approach is to build on a foundation of known pharmacology and clinical practice, then apply our R&D expertise and novel insights to create proprietary medicines with real value for patients and treatment systems. We will highlight for investors at our R&D Day how Alkermes employs a rigorous clinical development process that incorporates state-of-the-art clinical trial techniques and robust study designs so we can obtain data early in the development process to make rapid decisions about the most promising candidates in our pipeline.”
In addition, the company will provide details on later-stage pipeline candidates including: commercial plans for aripiprazole lauroxil, a once-monthly, long-acting atypical antipsychotic currently in Phase III development for the treatment of schizophrenia; review of the Phase II data for ALKS 5461, an opioid modulator with a novel mechanism for the treatment of major depressive disorder (MDD); and the clinical rationale and development plan, including initiation of a Phase II study for ALKS 3831, an oral compound designed as a broad spectrum antipsychotic treatment for schizophrenia.
“The three new drug candidates that we are unveiling exemplify the productivity of R&D at Alkermes — which now spans small molecules and biologics — and represent significant opportunities for us to address unmet needs for patients with major, chronic diseases: multiple sclerosis, pain and cancer,” said Elliot Ehrich, M.D., chief medical officer of Alkermes. “Our distinctive approach is to build on a foundation of known pharmacology and clinical practice, then apply our R&D expertise and novel insights to create proprietary medicines with real value for patients and treatment systems. We will highlight for investors at our R&D Day how Alkermes employs a rigorous clinical development process that incorporates state-of-the-art clinical trial techniques and robust study designs so we can obtain data early in the development process to make rapid decisions about the most promising candidates in our pipeline.”
